Summary: In a post hoc analysis of the SUSTAIN 6 trial (n=1139) confined to adults with type 2 diabetes and no diabetic kidney disease at baseline, once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease than placebo (odds ratio 0.56; 95% CI 0.42 to 0.74; p<0.0001), with an odds ratio of 0.51 (0.38 to 0.69) in those at high baseline risk and a number needed to treat of 7 in that high-risk group. Because this is a secondary, exploratory analysis, the finding is hypothesis-generating rather than confirmatory.
PICO Summary
| Element | Detail |
|---|---|
| Population | 1139 adults with type 2 diabetes and no diabetic kidney disease at baseline, drawn from the randomised, double-blind, placebo-controlled SUSTAIN 6 cardiovascular outcomes trial; multicentre, international. 28.7% developed diabetic kidney disease over follow-up; 952 of 1139 were classified as high baseline DKD risk by a validated prediction model. |
| Intervention | Once-weekly subcutaneous semaglutide 0.5 mg or 1.0 mg (GLP-1 receptor agonist), pooled in this analysis. |
| Comparison | Matching placebo within the double-blind trial. |
| Outcome | Development of diabetic kidney disease (UACR 30 mg/g or higher and/or eGFR below 60 mL/min/1.73 m2). Total population: odds ratio 0.56 (95% CI 0.42 to 0.74; p<0.0001). High-risk subgroup: odds ratio 0.51 (95% CI 0.38 to 0.69; p<0.0001), number needed to treat 7. Time to DKD development was significantly delayed; the benefit was largely driven by changes in urinary albumin-to-creatinine ratio (UACR). |
Semaglutide and primary prevention of diabetic kidney disease
SUSTAIN 6 post hoc · type 2 diabetes · no DKD at baseline
Semaglutide was associated with roughly half the odds of new-onset diabetic kidney disease versus placebo, with the largest absolute benefit in high-risk patients (NNT 7). As an exploratory post hoc analysis, it is hypothesis-generating, not confirmatory.
Expert Commentary
This post hoc analysis suggests that once-weekly semaglutide may lower the odds of new-onset diabetic kidney disease in people with type 2 diabetes who start with normal kidney status, with the largest absolute benefit seen in those at high baseline risk (number needed to treat of 7). The effect is biologically plausible and consistent with the known renal signal from the parent SUSTAIN 6 trial, and the magnitude is not implausibly large. The central caveat is design: this is a secondary, exploratory analysis of a trial not powered or randomised for this kidney prevention endpoint, the outcome leans heavily on UACR changes that can be transient, and the work was conducted with manufacturer involvement (Novo Nordisk authors), so the result should be read as hypothesis-generating rather than as proof that semaglutide prevents diabetic kidney disease. Can I use this with my patients? It is reasonable to factor in when selecting a glucose-lowering agent for a person with type 2 diabetes at high renal risk who already has another indication for a GLP-1 receptor agonist, but it does not by itself justify starting semaglutide purely for kidney protection in someone with normal albuminuria. A prospective trial with a pre-specified primary prevention endpoint and hard kidney outcomes is needed before this becomes a guideline-level recommendation.
References
Wang J, Yang J, Jiang W, Liu W, Shen Z, Gao Z, Chang B. Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: a post hoc analysis of the SUSTAIN 6 randomized controlled trial. Diabetes Obes Metab. 2024;26(11):5157-5166. doi:10.1111/dom.15860